Last €18.68 EUR
Change Today -0.063 / -0.34%
Volume 0.0
HO1 On Other Exchanges
Symbol
Exchange
Berlin
NASDAQ GS
As of 9:30 AM 08/28/14 All times are local (Market data is delayed by at least 15 minutes).

hologic inc (HO1) Snapshot

Open
€19.14
Previous Close
€18.74
Day High
€19.14
Day Low
€18.56
52 Week High
07/31/14 - €20.11
52 Week Low
04/28/14 - €14.39
Market Cap
5.2B
Average Volume 10 Days
21.0
EPS TTM
--
Shares Outstanding
277.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for HOLOGIC INC (HO1)

hologic inc (HO1) Related Businessweek News

No Related Businessweek News Found

hologic inc (HO1) Details

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women. The company’s Breast Health segment offers full field digital mammography, C-view, screen-film mammography, computer aided detection, Trident specimen radiography, and stereotactic breast biopsy systems; healthcome mammography, breast biopsy, and breast brachytherapy products; and breast tomosynthesis, Selenia full field digital mammography platform, SecurView workstation, MammoPad breast cushions, photoconductor coatings, and Sentinelle medical magnetic resonance imaging breast coils and workstations. Its Diagnostics segment provides APTIMA family of assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assays, instrumentation, Invader chemistry platform, Cervista HPV tests, ThinPrep system, fetal fibronectin tests, Procleix family of assays, and infectious disease and virology products. The company’s GYN Surgical segment offers NovaSure system to treat women suffering from abnormal uterine bleeding; MyoSure system for the hysteroscopic removal of fibroids; and Aquilex Fluid Control System to measure the inflow and outflow of fluid from the patient during hysteroscopic procedures. Its Skeletal Health segment provides discovery and horizon X-ray bone densitometers that assess the bone density of fracture sites; Sahara clinical bone sonometers, which assess the bone density of heels; and mini C-arm imaging systems to perform minimally invasive surgical procedures on a patient’s extremities. Hologic, Inc. sells its products through direct sales and service forces, and a network of independent distributors and sales representatives primarily in the United States, Europe, and the Asia-Pacific. The company has a strategic alliance with Quest Diagnostics Incorporated. Hologic, Inc. was founded in 1985 and is headquartered in Bedford, Massachusetts.

5,615 Employees
Last Reported Date: 11/26/13
Founded in 1985

hologic inc (HO1) Top Compensated Officers

Division President of Diagnostics
Total Annual Compensation: $349.1K
Chief Administrative Officer, Senior Vice Pre...
Total Annual Compensation: $425.0K
Senior Vice President of Corporate Strategy
Total Annual Compensation: $399.7K
Executive Officer
Total Annual Compensation: $599.5K
Compensation as of Fiscal Year 2013.

hologic inc (HO1) Key Developments

Hologic's Horizon DXA Platform for Osteoporosis, Cardiovascular Disease, and Obesity Assessment Receives Regulatory Approval in Canada

Hologic Inc. announced that Health Canada granted a medical device license for Horizon, a new DXA (dual-energy x-ray absorptiometry) imaging platform that assists in the assessment of three critical health problems - osteoporosis, cardiovascular disease, and obesity. The Horizon DXA platform is designed to offer improved precision, stability and throughput over current products. New, clinically relevant built-in enhancements include a high-resolution multi-element detector array with ceramic detector technology for improved bone mapping and image quality; a high-frequency pulsing power supply that offers greater system stability and future flexibility; and a filter drum to support future development initiatives. Built on Hologic proprietary technologies, Horizon offers expanded technical capabilities, workflow efficiencies and improved design components to meet clinician needs now and into the future. The Hologic Horizon DXA platform offers the following features: A Single Energy Femur Exam designed to allow clinicians to visualize potential atypical femur fractures, an unusual form of femur fracture which can occur as the result of bisphosphonate use. High Definition Instant Vertebral Assessment (IVA-HD) capability for significantly improved detection of vertebral fractures. An Abdominal Aortic Calcification feature through Hologic's IVA-HD technology designed to enable clinicians to visualize abdominal aortic calcifications, a significant predictor of cardiovascular disease. Advanced Body Composition assessment with visceral fat estimation to assist in the evaluation of metabolic health.

Hologic Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended June 30, 2014; Provides Earnings Guidance for the Fourth Quarter of 2014; Raises Earnings Guidance for the Year 2014

Hologic Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended June 30, 2014. For the quarter, the company reported total revenues of $632.6 million compared to $626.1 million reported in the same period last year. GAAP net income was $11.3 million, or $0.04 per diluted share, compared to a net loss of $11.0 million, or $0.04 per diluted share, versus prior year. Income from operations was $76.2 million against $61.1 million reported last year. Income before income taxes was $22.6 million against loss before income taxes of $7.0 million reported last year. Non-GAAP revenues were $632.6 million against $626.1 million reported last year. Non-GAAP net income was $102.4 million or $0.37 per diluted share against $103.2 million or $0.38 per diluted share reported last year. Adjusted EBITDA was $221.7 million against $227.4 million reported last year. Operating cash flow was $158 million for the quarter. For the nine months, the company reported total revenues of $1,870.1 million compared to $1,870.2 million reported in the same period last year. Net loss was $10.8 million or $0.04 per diluted share against net loss of $58.9 million or $0.22 per diluted share reported last year. Income from operations was $187.7 million against $129.9 million reported last year. Income before income taxes was $9.5 million against loss before income taxes of $88.0 million reported last year. Non-GAAP revenues were $1,870.1 million against $1,889.9 million reported last year. Non-GAAP net income was $299.7 million or $1.08 per diluted share against $298.9 million or $1.10 per diluted share reported last year. Adjusted EBITDA was $657.6 million against $666.7 million reported last year. For the fourth quarter of fiscal 2014, the company expects revenues of $630 million to $640 million, which excludes the one-time revenue contribution of approximately $20 million resulting from the amendment to the company's license agreement with Roka Bioscience Inc. The company expects non-GAAP EPS of $0.36 to $0.37. This excludes a $0.05 favorable impact due to the one-time revenue contribution of approximately $20 million. Including the one-time revenue contribution of approximately $20 million, the Company expects revenues of $650 million to $660 million and non-GAAP earning per share of $0.41 to $0.42. The company expects increase in gross margin percentage to approximately 63%. Based on the third quarter fiscal 2014 results and improved outlook for the fourth quarter, the company is raising its fiscal 2014 revenue and EPS guidance. The company is raising its fiscal 2014 revenue guidance to a range of $2.50 billion to $2.51 billion (from $2.46 billion to $2.49 billion provided on April 30, 2014). This excludes the one-time revenue contribution of approximately $20 million. The company is raising its fiscal 2014 non-GAAP EPS guidance to a range of $1.44 to $1.45 (as compared to $1.37 to $1.40 provided on April 30, 2014). This excludes a $0.05 favorable impact from the one-time revenue contribution of approximately $20 million. Including the one-time revenue contribution of approximately $20 million, the company expects revenues of $2.52 billion to $2.53 billion and non-GAAP EPS of $1.49 to $1.50. The company has generated approximately $400 million operating cash flow for year-to-date. The company expects to generate $500 million to $525 million operating cash flows for the year.

Hologic Inc. to Report Q3, 2014 Operating Results on Jul 30, 2014

Hologic Inc. announced that they will report Q3, 2014 operating results at 5:00 PM, Eastern Standard Time on Jul 30, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HO1:GR €18.68 EUR -0.063

HO1 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
DENTSPLY International Inc $47.57 USD -0.49
MEDNAX Inc $56.95 USD -0.29
Mettler-Toledo International Inc $271.70 USD +1.15
PerkinElmer Inc $44.77 USD +0.08
ResMed Inc $52.77 USD +0.27
View Industry Companies
 

Industry Analysis

HO1

Industry Average

Valuation HO1 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HOLOGIC INC, please visit www.hologic.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.